About-cancer/treatment/clinical-trials/thymoma-thymic-carcinoma
Nā ho'āʻo hoʻokolohua e mālama iā Tymoma a me thymic Carcinoma
Nā hoʻāʻo 1-12 o 12
ʻO Carboplatin a me Paclitaxel me Ramucirumab paha me ka mālama ʻole ʻana i nā mea maʻi me ka maʻi kūloko, recurrent, a i ʻole Metastatic thymic cancer ʻaʻole hiki ke hemo ʻia e ka ʻoki kino.
Ke aʻo nei kēia mahele II i ka hoʻokolohua ʻana i ka maikaʻi o ka hana ʻana o ka carboplatin a me paclitaxel me ka ʻole o ka ramucirumab i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai thymic i palahalaha aʻe i nā kiko kokoke a i ʻole nā lymph node (holomua kūloko), ua hoʻi mai (recurrent), ua hoʻolaha ʻia i nā wahi ʻē aʻe o ka kino (metastatic) a i ʻole hiki ʻole ke hemo e ke ʻoki. ʻO nā lāʻau i hoʻohana ʻia i ka chemotherapy, e like me ka carboplatin a me paclitaxel, hana i nā ala like ʻole e hōʻoki ai i ka ulu ʻana o nā hunaola tumora, ma ka luku ʻana paha i nā hunaola, ma ke kāpae ʻana iā lākou mai ka hoʻokaʻawale ʻana, a i ʻole ke kū ʻana iā lākou mai ka hoʻolaha ʻana Hoʻopilikia paha nā monoclonal antibodies, e like me ramucirumab, me ka hiki ke ulu a pālahalaha nā pūnaewele tumora. ʻAʻole i ʻike ʻia inā e hāʻawi ʻoi aku ka maikaʻi o ka hāʻawi ʻana i ka carboplatin a me paclitaxel me ka ʻole o ka ramucirumab i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai thymic.
Kahi: 254 mau wahi
Ke aʻo ʻana o XmAb®20717 i nā kumuhana me nā Tumors Solid Advanced i wae ʻia
ʻO kēia kahi pae 1, nā mahele lāʻau he nui, e piʻi nei i ka hoʻonui ʻana o ka lāʻau e wehewehe ai i ka MTD / RD a me ka regimen o XmAb20717, e wehewehe i ka palekana a me ka hoʻomanawanui ʻana, e loiloi iā PK a me ka immunogenicity, a me ka loiloi mua i ka hana anti-tumor o XmAb20717 i nā kumuhana me ke koho nā tumors paʻa holomua.
Kahi: 15 mau wahi
ʻO Nivolumab a me Vorolanib i ka mālama ʻana i nā mea maʻi me nā maʻi puʻuwai liʻiliʻi liʻiliʻi liʻiliʻi a me nā tumors Thoracic Refractory.
Ke aʻo nei kēia mahele I / II i nā hopena a me ka mahele lāʻau ʻoi loa o ka vorolanib ke hāʻawi ʻia me ka nivolumab i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi a me nā tumacic thoracic e pane ʻole i ka mālama ʻana (refractory). Immunotherapy me nā monoclonal antibodies, e like me ka nivolumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a ke hoʻopilikia paha i ka hiki i nā pūpū tumora ke ulu a pālahalaha. Hiki i ka Vorolanib ke ho'ōki i ka ulu ʻana o nā hunaola tumele ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell. ʻOi aku ka maikaʻi o ka hāʻawi ʻana i ka nivolumab a me ka vorolanib i ka mālama ʻana i nā mea maʻi me ka maʻi ʻaʻai liʻiliʻi liʻiliʻi liʻiliʻi a me nā puʻupuʻu pūpū.
Kahi: 7 mau wahi
Ke aʻo ʻana iā SO-C101 a me SO-C101 i ka hui pū ʻana me Pembro i nā maʻi o nā mākua me nā tumors paʻa / Metastatic Solid.
ʻO kahi multicenter open-label phase 1 / 1b hoʻopaʻa haʻawina e loiloi i ka palekana a me ka pono mua o SO-C101 ma ke ʻano he monotherapy a me ka hui pū ʻana me pembrolizumab i nā mea maʻi me nā tumors paʻa kūʻē / metastatic i wae ʻia.
Kahi: 2 mau wahi
ʻO ka loiloi wikiwiki a me ka loiloi pane o ka hoʻohui ʻana i nā Agena Anti-Neoplastic i nā Tumors Rare (CANCER RARE) Hoʻokolokolo: RARE 1 Nilotinib a me Paclitaxel
ʻIke: ʻO nā kānaka me nā maʻi ʻaʻai laha ʻole pinepine ʻia nā koho lapaʻau ʻana. ʻAʻole maopopo ka biology o nā kanesa laha ʻole. Makemake nā kānaka noiʻi e loaʻa i nā lāʻau ʻoi aku ka maikaʻi no kēia mau maʻi maʻi maʻi. Makemake lākou e hoʻāʻo i nā lāʻau 2 i lawe ʻokoʻa ʻia, ua kōkua i ka poʻe me nā maʻi maʻi maʻi ʻole. Makemake lākou e ʻike inā hiki i kēia mau lāʻau ke hana i nā maʻi maʻi lahilahi e hōʻemi a kū i ka ulu ʻana. Pahuhopu: E aʻo inā pono ka nilotinib a me ka paclitaxel i ka poʻe me nā maʻi ʻaʻai liʻiliʻi. ʻO nā kūpono: ʻO ka poʻe nona ka makahiki 18 a ʻoi aku ka makahiki i loaʻa kahi maʻi ʻaʻai laha ʻole, holomua i holomua ma hope o ka loaʻa ʻana o ka lāʻau maʻamau, a i ʻole no kahi ʻano lāʻau kūpono. Hoʻolālā: E paʻi ʻia nā mea komo me ka mōʻaukala olakino a me ka hoʻāʻo kino. E loaʻa iā lākou nā hoʻokolohua koko a me ka mimi. E loaʻa iā lākou kahi hōʻoia hāpai inā pono. E loaʻa iā lākou kahi electrocardiogram e nānā ai i ko lākou puʻuwai. E loaʻa iā lākou i nā kiʻi paʻi kiʻi e ana i ko lākou tumors. E hana hou nā mea komo i nā hoʻokolohua kānana i ka wā o ka hoʻopaʻa. E loaʻa i nā mea komo nā nilotinib a me paclitaxel. Hāʻawi ʻia nā lāʻau i nā pōʻaiapuni he 28 mau lā. ʻO Nilotinib kahi capsule i lawe ʻia e ka waha i ʻelua mau manawa i ka lā. E hāʻawi pinepine ʻia ʻo Paclitaxel e ka laina peripheral a i ʻole ka laina waena i hoʻokahi manawa i kēlā me kēia pule no nā pule he 3 mua o kēlā me kēia pōʻaiapuni. Mālama nā mea komo i ka diary lāʻau. E alualu lākou ke lawe lākou i nā lāʻau i hoʻopaʻa ʻia a me nā hopena ʻē aʻe i loaʻa iā lākou. Loaʻa i nā mea komo i nā biopsies tumo koho. Hiki i nā mea komo ke noho ma ke aʻo ʻana a hiki i ka wā e māhuahua ai ko lākou maʻi a i ʻole loaʻa iā lākou nā hopena i hiki ʻole ke hoʻomanawanui. E kāhea ka poʻe i komo ma hope o ke kelepona ʻana ma kahi o 30 mau lā ma hope o ka lawe ʻana i ka hopena hope loa o nā lāʻau noiʻi. E loaʻa i nā mea komo nā nilotinib a me paclitaxel. Hāʻawi ʻia nā lāʻau i nā pōʻaiapuni he 28 mau lā. ʻO Nilotinib kahi capsule i lawe ʻia e ka waha i ʻelua mau manawa i ka lā. E hāʻawi pinepine ʻia ʻo Paclitaxel e ka laina peripheral a i ʻole ka laina waena i hoʻokahi manawa i kēlā me kēia pule no nā pule he 3 mua o kēlā me kēia pōʻaiapuni. Mālama nā mea komo i ka diary lāʻau. E alualu lākou ke lawe lākou i nā lāʻau i hoʻopaʻa ʻia a me nā hopena ʻē aʻe i loaʻa iā lākou. Loaʻa i nā mea komo i nā biopsies tumo koho. Hiki i nā mea komo ke noho ma ke aʻo ʻana a hiki i ka wā e māhuahua ai ko lākou maʻi a i ʻole loaʻa iā lākou nā hopena i hiki ʻole ke hoʻomanawanui. E kāhea ka poʻe i komo ma hope o ke kelepona ʻana ma kahi o 30 mau lā ma hope o ka lawe ʻana i ka hopena hope loa o nā lāʻau noiʻi. E loaʻa i nā mea komo nā nilotinib a me paclitaxel. Hāʻawi ʻia nā lāʻau i nā pōʻaiapuni he 28 mau lā. ʻO Nilotinib kahi capsule i lawe ʻia e ka waha i ʻelua mau manawa i ka lā. E hāʻawi pinepine ʻia ʻo Paclitaxel e ka laina peripheral a i ʻole ka laina waena i hoʻokahi manawa i kēlā me kēia pule no nā pule he 3 mua o kēlā me kēia pōʻaiapuni. Mālama nā mea komo i ka diary lāʻau. E alualu lākou ke lawe lākou i nā lāʻau i hoʻopaʻa ʻia a me nā hopena ʻē aʻe i loaʻa iā lākou. Loaʻa i nā mea komo i nā biopsies tumo koho. Hiki i nā mea komo ke noho ma ke aʻo ʻana a hiki i ka wā e māhuahua ai ko lākou maʻi a i ʻole loaʻa iā lākou nā hopena i hiki ʻole ke hoʻomanawanui. E kāhea ka poʻe i komo ma hope o ke kelepona ʻana ma kahi o 30 mau lā ma hope o ka lawe ʻana i ka hopena hope loa o nā lāʻau noiʻi. E hāʻawi pinepine ʻia ʻo Paclitaxel e ka laina peripheral a i ʻole ka laina waena i hoʻokahi manawa i kēlā me kēia pule no nā pule he 3 mua o kēlā me kēia pōʻaiapuni. Mālama nā mea komo i ka diary lāʻau. E alualu lākou ke lawe lākou i nā lāʻau i hoʻopaʻa ʻia a me nā hopena ʻē aʻe i loaʻa iā lākou. Loaʻa i nā mea komo i nā biopsies tumo koho. Hiki i nā mea komo ke noho ma ke aʻo ʻana a hiki i ka wā e māhuahua ai ko lākou maʻi a i ʻole loaʻa iā lākou nā hopena i hiki ʻole ke hoʻomanawanui. E kāhea ka poʻe i komo ma hope o ke kelepona ʻana ma kahi o 30 mau lā ma hope o ka lawe ʻana i ka hopena hope loa o nā lāʻau noiʻi. E hāʻawi pinepine ʻia ʻo Paclitaxel e ka laina peripheral a i ʻole ka laina waena i hoʻokahi manawa i kēlā me kēia pule no nā pule he 3 mua o kēlā me kēia pōʻaiapuni. Mālama nā mea komo i ka diary lāʻau. E alualu lākou ke lawe lākou i nā lāʻau i hoʻopaʻa ʻia a me nā hopena ʻē aʻe i loaʻa iā lākou. Loaʻa i nā mea komo i nā biopsies tumo koho. Hiki i nā mea komo ke noho ma ke aʻo ʻana a hiki i ka wā e māhuahua ai ko lākou maʻi a i ʻole loaʻa iā lākou nā hopena i hiki ʻole ke hoʻomanawanui. E kāhea ka poʻe i komo ma hope o ke kelepona ʻana ma kahi o 30 mau lā ma hope o ka lawe ʻana i ka hopena hope loa o nā lāʻau noiʻi.
Kahi: National Institutes of Health Clinical Center, Bethesda, Maryland
ʻO Pembrolizumab a me Sunitinib Malate i ka mālama ʻana i nā mea komo me ka Metastatic Refractory a i ʻole ke kanesa thymic hiki ʻole ke pale ʻia.
Ke aʻo nei kēia pae II i ka maikaʻi o ka hana ʻana o ka pembrolizumab a me ka sunitinib malate i ka mālama ʻana i nā mea komo me ka maʻi ʻaʻai thymic i pāhola ʻia i nā wahi ʻē aʻe o ke kino a i ʻole hiki ke lawe ʻia e ka ʻoki kino a pane ʻole i ka lāʻau. Monoclonal antibodies, e like me pembrolizumab, hiki ke hoʻopilikia i ka hiki i nā pūpū tumora ke ulu a pālahalaha. Sunitinib malate hiki ke hoʻōki i ka ulu ʻana o nā hunaola tumele ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell. ʻOi aku ka maikaʻi o ka hāʻawi ʻana i ka pembrolizumab a me ka sunitinib malate i ka mālama ʻana i ka maʻi ʻaʻai thymic.
Kahi: Ke Kulanui ʻo ʻAmelika Hui Pū ʻIa Comprehensive Cancer Center, Columbus, Ohio
Pembrolizumab i ka mālama ʻana i nā mea komo me ka Thymoma undresectable a i ʻole ka maʻi ʻaʻai thymic
Ke nānā nei kēia pae I ka ʻaoʻao i nā hopena a me ka mahele lāʻau maikaʻi loa o ka pembrolizumab i ka mālama ʻana i nā mea komo me ka thymoma a i ʻole ka maʻi ʻaʻai thymic i hiki ʻole ke hemo e ke ʻoki. Immunotherapy me nā monoclonal antibodies, e like me pembrolizumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a hiki ke hoʻopilikia i ka hiki o nā tumele keola e ulu a pālahalaha aku.
Kahi: MD Anderson Cancer Center, Houston, Texas
Selinexor i ka mālama ʻana i nā mea komo me ka Tummic Epithelial Advanced
Ke aʻo nei kēia pae II i ka maikaʻi o ka hana a selinexor i ka mālama ʻana i nā mea komo me ka tumm epithelial thymic i palahalaha aʻe i nā wahi ʻē aʻe o ke kino. Hiki paha iā Selinexor ke hoʻopau i ka ulu ʻana o nā hunaola tumola ma ke kāpae ʻana i kekahi o nā protein e pono ai no ka ulu ʻana o ka cell
Kahi: 2 mau wahi
ʻO Bintrafusp Alfa (M7824) i nā kumuhana me Thymoma a me thymic Carcinoma
Ka Ike Kahua: ʻO thymoma a me thy carmoma thymic nā maʻi o ka thymus. ʻO ka chemotherapy a me ka Platinum ka lāʻau maʻamau no kēia mau maʻi. Akā i nā manawa he nui, hoʻi ka maʻi ma hope o ka mālama ʻana. Makemake nā kānaka noiʻi inā hiki i kahi lāʻau hou ke kōkua. Nive Pahuhopu: E ʻike ai inā he lapaʻau maikaʻi ʻo bintrafusp alfa (M7824) no ka thymoma a me ka carmoma thymic. ʻO nā kūpono: ʻO ka poʻe nona ka makahiki 18 a ʻoi paha i loaʻa iā thymoma a i ʻole ka maʻi ʻaʻai thymic a hoʻi ko lākou maʻi a hoʻi a holomua paha ma hope o ka lapaʻau ʻana me ka liʻiliʻi ma kahi o ka platinum-i loaʻa i kahi hoʻolālā chemotherapy, a i ʻole hōʻole i ka hoʻolālā maʻamau maʻamau: e nānā ʻia nā mea komo ma lalo o kahi kaʻina kaʻawale. E nānā hou ʻia kā lākou kauka, lāʻau lapaʻau, a me ka mōʻaukala lapaʻau. E loaʻa iā lākou kahi biopsy tumo inā ʻaʻohe o lākou hāpana. E loaʻa i nā mea komo ka lāʻau aʻo i hoʻokahi manawa i kēlā me kēia 2 pule ma ke ʻano he infusion intravenous. No kēia, hoʻokomo ʻia kahi ʻōmole ea liʻiliʻi i loko o ka aa lima. I loko o ke aʻo ʻana, e komo ana nā mea i kēia mau mea: Hōʻike lāʻau lapaʻau Hōʻikeʻike kino i kā lākou mau ʻōuli a me ko lākou hiki ke hana i kā lākou hana maʻamau Kino a me ka mimi hoʻāʻo ʻiʻo mākala ʻūhā (e hoʻohana ana iā MRI) Nānā Tumor (e hoʻohana ana iā MRI a i ʻole CT Hōʻike ka thyroid gland i ka nānā ʻana i ka ʻili. Hiki i nā mea komo ke loaʻa i nā biopsies tumo. E hoʻohana ʻia kekahi o ko lākou koko a me nā laʻana biopsy no ka hoʻāʻo ʻana i nā gen. Hiki i nā mea komo ke lawe i ka lāʻau aʻo a hiki i ka wā e ulu ai ka maʻi a i ʻole hiki ʻole iā lākou ke ʻae i ka lāʻau. E kipa hou aku nā mea i komo ma 2 a me 6 mau pule ma hope o ka hōʻoki ʻana i ka lāʻau. A laila e loaʻa iā lākou nā kipa ukali wā lōʻihi i kēlā me kēia 3 mahina. Pākuʻi ʻia paha kēia mau mea i ke kiʻi paʻi kiʻi. Hiki ke hana i nā kipa ma ke kelepona, me nā scans (inā pono) i hana ʻia ma kā lākou keʻena kauka. Kahi:
Abexinostat a me Pembrolizumab i ka mālama ʻana i nā mea maʻi me MSI-High Kūloko Kūloko a i ʻole Metastatic Solid Tumors
Ke aʻo nei kēia mahele wau i ka mahele lāʻau maikaʻi loa a me nā hopena ʻē aʻe o ka abexinostat a me ka maikaʻi o ka hana ʻana me ka hāʻawi pū ʻia ʻana me ka pembrolizumab i ka mālama ʻana i nā maʻi me ka tumors microsatelit (MSI) tumors paʻa i pāhola ʻia i nā kiko kokoke a i ʻole nā lymph node (holomua kūloko) a i ʻole nā wahi ʻē aʻe. i ke kino (metastatic). Hiki paha i ka Abexinostat ke hoʻōki i ka ulu ʻana o nā hunaola tumele ma ke kāpae ʻana i kekahi o nā ʻenema e pono ai no ka ulu ʻana o ka cell. Immunotherapy me nā monoclonal antibodies, e like me pembrolizumab, hiki ke kōkua i ke kino ʻōnaehana pale kaua i ka maʻi ʻaʻai, a hiki ke hoʻopilikia i ka hiki o nā tumele keola e ulu a pālahalaha aku. ʻOi aku ka maikaʻi o ka hāʻawi ʻana i ka abexinostat a me ka pembrolizumab i ka mālama ʻana i nā mea maʻi me nā tumors paʻa.
Kahi: UCSF Medical Center-Mount Ziona, Kapalakiko, Kaleponi
ʻO Oral TrkA Inhibitor VMD-928 no ka mālama ʻana i nā Tumors paʻa paʻa mua a i ʻole Lymphoma
ʻO kēia kahi multicenter, open-label, Phase 1 hoʻopaʻa haʻawina waha waha VMD-928 i nā mākua me nā tumors paʻa holomua a i ʻole lymphoma i holomua a pane ʻole paha i nā lāʻau i loaʻa a no laila ʻaʻohe kūlana maʻamau a i ʻole kahi curative therapy e kū nei.
Kahi: Ke Kulanui o ka Hope Comprehensive Cancer Center, Duarte, Kaleponi
ʻO kahi Pilot Study e noiʻi i ka palekana a me ka hana haukapila o Avelumab (MSB0010718C) ma Thymoma a me thymic Carcinoma ma hope o ka holomua ʻana ma ka Chemotherapy Platinum-Base.
Ka Ike Hou: ʻO Tymoma a me thy carmoma thymic nā maʻi ʻohe i hoʻomaka ʻia i ka gland thymus. ʻO ka chemotherapy a me ka Platinum ka hoʻomaʻamaʻa maʻamau no lākou. Akā ʻaʻole maʻamau, hoʻi ka maʻi a makemake ka poʻe i nā lāʻau hou aku e mālama i ka maʻi ʻaʻai mai ka ulu ʻana. Hiki i ka lāʻau Avelumab ke kōkua i ka ʻōnaehana pale pale i ke kanesa. Pahuhopu: E hoʻāʻo inā palekana a palekana maikaʻi ʻia ka avelumab, a maikaʻi i ka mālama ʻana i ka relapsed a i ʻole ka refactory thymoma a me ka carmoma thymic. ʻO nā kūpono: ʻO nā makahiki he 18 a ʻoi aku paha me ka thymoma a i ʻole carmoma thymic i hoʻi mai a i holomua paha ma hope o ka hoʻolālā ʻana o ka chemotherapy i ka platinum: E hōʻike ʻia nā mea komo me: ke kino. - Hōʻoiaʻiʻo kino - Mōʻaukala olakino - Biopsy: hoʻopau ke kuikele i kahi ʻāpala. Hiki i nā laʻana mai kahi hana i hala, ʻoiai makemake ʻia e hana i kahi biopsy hou. E mālama ka poʻe komo i ka hoʻomaʻamaʻa ma nā wā he 2 mau pule. E hoʻomau lākou a hiki i ka hopena o nā ʻaoʻao a i ʻole e ʻino ka maʻi. ʻO nā kipa ma nā manawa aʻe e koi ʻia no kēlā me kēia kaʻanuʻu. ʻO nā mea maʻi e pane i ka mālama ʻana a i ʻole kūpaʻa paʻa ma hope o 12 mau mahina o ka hoʻomaʻamaʻa e hiki ke hana i kahi lāʻau de-escalation regimen e hoʻomau i ka therapy. - Kēlā me kēia 2 mau pule: E loaʻa avelumab i nā mea e komo ai ma o ka hoʻokomo ʻana i ke aa (IV). E loaʻa iā lākou ka diphenhydramine (benadryl) a me ka acetaminophen (tylenol) e ka waha a i ʻole IV ma mua o ka loaʻa ʻana o ka avelumab e hoʻemi ai i nā manawa o ka hoʻomohala ʻana i ka avelumab. E loaʻa lākou i ke koko, ka mimi, a me nā hoʻokolohua naʻau i kēlā me kēia manawa. - Pōʻaiapuni 4 a me 7, a laila i kēlā me kēia 6 pule: E nānā ʻia nā scans e nānā ai i ka shrinkage a i ʻole ka ulu ʻana o ka tumo. - Pōʻaiapuni 4: Hāʻawi ʻia i nā mea komo kahi manawa e hana i kahi biopsy. - 2-4 mau pule ma hope o ka hoʻōki ʻana i ka lāʻau ʻana: e hoʻokō ʻia ke koko, ka mimi, a me nā hoʻokolohua puʻuwai. Hiki paha i nā mea komo ke nānā i kahi scan. - 10 mau pule ma hope o ka hoʻōki ʻana i ka lāʻau ʻana: Koko, mimi, a me nā hoʻokolohua puʻuwai. - Ma kahi o 6 mau mahina ma hope o ka hoʻōki ʻana i ka lāʻau, a laila i kēlā me kēia 3 mau mahina: E nānā nā mea komo a ʻae i nā hoʻokolohua genetic i ko lākou koko a me nā kiko kiko.
Kahi: National Institutes of Health Clinical Center, Bethesda, Maryland
E hoʻohā i ka ʻōlelo hoʻohou auto-refresher